Study #2021-0451
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
MD Anderson Study Status
Not Accepting
Treatment Agent
BST-236
Description
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20 adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study. Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients will be followed for 1 year in the study and additional 1 year post study follow-up.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
Study phase:
Phase II
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-877-685-1904
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.